ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Monday, November 9, 2020

12:00PM-12:50PM: Abstract Number: 1955

High-throughput Identification of Functional Regulatory SNPs Associated with Systemic Lupus Erythematosus

Genetics, Genomics & Proteomics (1953–1957)

12:00PM-12:50PM: Abstract Number: 1966

Improving Value Concordant Care Through Increased Use of Subcutaneous Methotrexate in Rheumatoid Arthritis

Measures & Measurement of Healthcare Quality (1963–1967)

12:00PM-12:50PM: Abstract Number: 2017

Machine Learning Identifies an Association Between Pre-existing Radiographic Damage and Long-term Clinical Outcomes with Secukinumab Therapy in Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II (2013–2017)

12:00PM-12:50PM: Abstract Number: 1970

Mimicking Cytokine-driven Key Features of Arthritis Using a Human in Vitro 3D Joint Model

Osteoarthritis & Joint Biology – Basic Science (1968–1972)

12:00PM-12:50PM: Abstract Number: 1972

NGF-Responsive Neurons Are Sensitized in Experimental Osteoarthritis

Osteoarthritis & Joint Biology – Basic Science (1968–1972)

12:00PM-12:50PM: Abstract Number: 2015

Prevalence and Distribution of Peripheral Musculoskeletal Manifestations in Axial Spondyloarthritis, Peripheral Spondyloarthritis and Psoriatic Arthritis: Results of the International, Cross-sectional ASAS-PerSpA Study

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II (2013–2017)

12:00PM-12:50PM: Abstract Number: 1965

Reducing Delays for Biologic Medication Approval in Outpatient Rheumatology

Measures & Measurement of Healthcare Quality (1963–1967)

12:00PM-12:50PM: Abstract Number: 1953

Somatic Mutations in a Single Residue of UBA1 Cause VEXAS, a Severe Adult-Onset Rheumatic Disease Presenting as Relapsing Polychondritis, Polyarteritis Nodosa, or Giant Cell Arteritis

Genetics, Genomics & Proteomics (1953–1957)

12:00PM-12:50PM: Abstract Number: 2013

Substantial Lifetime Risk of Developing Ankylosing Spondylitis (Axial Spondyloarthritis) for Relatives. Evidence from a 35-Year Follow-up Family Study of a Swiss Cohort

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II (2013–2017)

12:00PM-12:50PM: Abstract Number: 1969

The Dynamics of Macrophage Sub-Populations in the Inflammatory Phase Following Joint Trauma

Osteoarthritis & Joint Biology – Basic Science (1968–1972)

12:00PM-12:50PM: Abstract Number: 2014

The Relative Diagnostic Utility of Inflammatory Back Pain Criteria in an Inception Cohort of Patients with Psoriasis, Iritis, and Colitis Presenting with Undiagnosed Back Pain

Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II (2013–2017)

12:00PM-12:50PM: Abstract Number: 1963

Variation in Quality of Care Among Patient Sociodemographic Groups in RISE Practices

Measures & Measurement of Healthcare Quality (1963–1967)

3:00PM-3:50PM: Abstract Number: 1952

Activated Memory T Cells Produce Ligands That Cause NF-κB-dependent Inflammatory Activation of the Endothelium: Identification of Novel Therapeutic Targets

Cytokines & Cell Trafficking (1948–1952)

3:00PM-3:50PM: Abstract Number: 2001

Adverse Effects of Low Dose Methotrexate: Adjudicated Hematologic Outcomes in a Large Randomized Double-blind Placebo-controlled Trial

RA – Treatments II: Potential Harms & Adverse Events (1998–2002)

3:00PM-3:50PM: Abstract Number: 1949

CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro

Cytokines & Cell Trafficking (1948–1952)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].